Sažetak
Background: To investigate the correlations of the gene polymorphisms of angiotensin-converting enzyme 2 (ACE2) with the onset and prognosis of hypertrophic cardiomyopathy (HCM), so as to provide references for the early prevention and precise treatment of HCM in the future.
Methods: In this case-control study, a total of 100 HCM patients (HCM group) and 100 healthy people receiving physical examination who had matched age, gender and race (Control group) were collected. The single nucleotide polymorphisms (rs102312, rs102883 and rs119247) in the promoter region of ACE2 gene were genotyped by means of conformation-difference gel electrophoresis. Whether the distribution frequency of ACE2 genotypes is in agreement with the law of genetic equilibrium was examined using chi-square test. Meanwhile, the correlations of different polymorphisms and alleles in the promoter region of ACE2 gene with the onset and prognosis of HCM were analyzed.
Results: The Hardy-Weinberg equilibrium analysis showed that all the three polymorphisms of ACE2 gene were in agreement with the law of genetic equilibrium (p>0.05). According to the results of genetic association analysis, the polymorphism rs102312 and its alleles in the promoter region of ACE2 gene were correlated with the occurrence of HCM (p<0.05), while the polymorphisms rs102883 and rs119247 as well as their alleles had no associations with the occurrence of HCM (p>0.05). Furthermore, it was found that the cardiac function and prognosis of HCM patients carrying genotype GG of polymorphism rs102312 were poorer than those of patients carrying genotype TT (p<0.05).
Conclusion: The polymorphism rs102312 in the promoter region of ACE2 gene is associated with the onset of HCM in patients, and HCM patients carrying the genotype GG of polymorphism rs102312 have a poorer clinical prognosis.
Ključne reči
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.